Skip to main content

Unique approach to improving neurological function after stroke with SIN020


The aim of this project is to develop a business plan to guide clinical development and commercialisation of SIN020; a glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) to promote recovery of the injured stroke brain. Every year, 1 million people in Europe have a stroke and the healthcare and non-healthcare cost is estimated at EUR 45 billion. The only treatment option available for restoring neurological function in stroke patients is rehabilitation, which has limited effect. Since there is a 34% anticipated rise in the total number of stroke events between 2015 and 2035, there is a pressing need for a pharmacological intervention to help restore function after stroke. Sinntaxis is developing SIN020, a repurposed investigational drug that has previously been in clinical development for another indication and can therefore enter straight in to a Phase II clinical trial. In animal models, mGluR5 NAM has been shown to help reverse lost functions in animal models of stroke and we aim to translate this exciting preclinical data to clinically validated results. The current proposed Phase 1 project will facilitate in the development process and help define clinical and business strategies. SME Instrument funding will allow SIN020 to take a substantial step along the path of commercialisation.

Field of science

  • /medical and health sciences/basic medicine/neurology/stroke
  • /medical and health sciences/clinical medicine/physiotherapy
  • /social sciences/economics and business

Call for proposal

See other projects for this call

Funding Scheme

SME-1 - SME instrument phase 1


Medicon Village Scheelevagen 2
223 81 Lund
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000